Get the Stockscreener App
32.06
13.77%
-5.12
After Hours:
32.30
0.24
+0.75%
Biohaven Ltd Stock (BHVN) Latest News
Biohaven Ltd. SEC 10-K Report - TradingView
Piper Sandler maintains Biohaven stock with $76 target By Investing.com - Investing.com South Africa
Piper Sandler maintains Biohaven stock with $76 target - Investing.com India
Biohaven’s ion channel drug fails pivotal bipolar mania study - Endpoints News
Strong Immunoglobulin Reduction Data Positions Biohaven's BHV-1300 As Potential Autoimmune Therapy - Benzinga
Biohaven down 10% on quarterly EPS miss, bipolar mania asset study - Seeking Alpha
Biohaven’s BHV-1300 shows promise in IgG reduction By Investing.com - Investing.com Canada
Biohaven’s BHV-1300 shows promise in IgG reduction - Investing.com
Biohaven reports ‘positive’ data from study of BHV-1300 - TipRanks
Earnings Flash (BHVN) BIOHAVEN LTD. Posts Q4 Loss $-1.71 Per Share, vs. FactSet Est of $-1.49 - Marketscreener.com
Biohaven Pharma (BHVN) Reports Positive Degrader Data Achieving > 80% Sustained Reductions in Total IgG with Potential First-in-Class BHV-1300 - StreetInsider.com
Biohaven Reports Positive Degrader Data Achieving > 80% Sustained Reductions in Total IgG with Potential First-in-Class BHV-1300 - PR Newswire
Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2024 Financial Results - PR Newswire
Biohaven's Exciting Year Of Catalysts (NYSE:BHVN) - Seeking Alpha
(BHVN) Technical Pivots with Risk Controls - Stock Traders Daily
Biohaven's troriluzole gains FDA priority review for SCA - MSN
Biohaven (NYSE:BHVN) Now Covered by Deutsche Bank Aktiengesellschaft - MarketBeat
Biohaven stock rises following FDA review and Deutsche Bank's buy rating - MSN
Biohaven (NYSE:BHVN) Shares Gap UpWhat's Next? - MarketBeat
WCM Investment Management LLC Takes Position in Biohaven Ltd. (NYSE:BHVN) - MarketBeat
Mississippi to receive$162.2K of $59.7M Settlement Over Alleged Biohaven Kickbacks - Vicksburg Daily News
Biohaven Ltd. Receives FDA Priority Review for Troriluzole, Boosting Investor Confidence - TipRanks
Why Biohaven Stock Triumphed on Tuesday - The Motley Fool
Biohaven: NDA Review Of Troriluzole Isn't Only 2025 Catalyst On Deck - Seeking Alpha
Biohaven, Ecolab, Firefly - TradingView
Biohaven: Highly Priced Biotech With Broad Pipeline But No Revenues (NYSE:BHVN) - Seeking Alpha
Biohaven stock rises following FDA review and Deutsche Bank’s buy rating - Investing.com Nigeria
Biohaven stock rises following FDA review and Deutsche Bank's buy rating By Investing.com - Investing.com South Africa
Biohaven Says FDA Grants Priority Review to Neurodegenerative Disorder Drug; Shares Rise - Marketscreener.com
Biohaven’s troriluzole NDA in spinocerebellar ataxia accepted by the FDA - TipRanks
Why Biohaven Ltd. Shares Are Tumbling? - TipRanks
Biohaven Announces FDA Acceptance and Priority Review of Troriluzole New Drug Application for the Treatment of Spinocerebellar Ataxia - Quantisnow
Jennison Associates LLC Makes New $3.64 Million Investment in Biohaven Ltd. (NYSE:BHVN) - MarketBeat
China Universal Asset Management Co. Ltd. Makes New $575,000 Investment in Biohaven Ltd. (NYSE:BHVN) - MarketBeat
Biohaven Kickback Case Settled For $59M - NewsBreak
SG Americas Securities LLC Has $336,000 Holdings in Biohaven Ltd. (NYSE:BHVN) - Defense World
Attorney General’s Office secures $2.3M in multistate action from Pfizer-owned company - Florida Politics
Biohaven Ltd.’s Promising Outlook for Troriluzole in Spinocerebellar Ataxia Amidst FDA Decision - TipRanks
Biohaven FY2025 EPS Forecast Decreased by Leerink Partnrs - MarketBeat
(BHVN) Technical Data - Stock Traders Daily
Leerink Partnrs Decreases Earnings Estimates for Biohaven - Defense World
Nebraska Joins in Settling Kickback Allegations against Biohaven Pharmaceutical Holding Company Ltd. - Rural Radio Network
6.45%
1.23%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):